Ocugen Reports 1Q22 Within Expectations. Ocugen reported a loss of $18.0 million or $(0.09) per share, larger than our expected loss of $15.8 million or $(0.06) per share. During the quarter, the company continued to work with US and Canadian regulators toward Covaxin approval. The Phase 1/2 OCU400 gene therapy trial continues to enroll patients. Cash balance at the end of 1Q was $129.9 million.Ocugen Continues To Work Toward Covaxin Approval. The US bioequivalence Phase 2/3 immuno-bridging study stopped new enrollment due to undisclosed issues at Bharat Biotech’s manufacturing plant. As these issues are being addressed, the company continues to speak with the FDA to lift the clinical hold and to determine requirements for the BLA submission. Read More >>